Recently, a slew of molecular markers, such as BRAF [9], RAS [10], RET-PTC [11], TERT [12], and other gene mutations and/or rearrangement, have been proposed to facilitate the diagnosis and prognosis of ThyC patients. This evidence concerns the gene RET and thymic carcinoma.